Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 14;13:5399. doi: 10.1038/s41467-022-33034-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Experimental design. b Total blood cholesterol (n = 13 in CD group, n = 10 in HFHCD group, pool of two independent experiments). c Tumor growth evolution at day 7 (n = 23 in CD group, n = 17 in HFHCD group), day 9 (n = 35 in CD group, n = 24 in HFHCD group), day 12 (n = 22 in CD group, n = 13 in HFHCD group) and day 15 (n = 26 in CD group, n = 19 in HFHCD group). Data were pooled from five experiments. d tumor weight at the time of sacrifice (n = 21 mice/group, pool of five independent experiments). Representative microphotographies of tumor sections after hematoxilin/eosin coloration. e Quantification of CD45⁺ leukocytes in the tumor, by flow cytometry (n = 8 mice/group for evaluation at day 3, 5, 7 and n = 8/group at day 9. Data were pooled from three experiments). Flow cytometry analysis of f main subsets of leukocytes (%) in tumors at the time of sacrifice (n = 13 in CD group and n = 10 in HFHCD group), g and of M-MDSC (CD11b⁺ Ly6C^hi), PNM-MDSC (CD11b⁺ Ly6C^lo Ly6G⁺) and TAM (CD11b⁺Ly6C^lo Ly6G^- F4/80⁺) among CD11b⁺ cells in the tumor (n = 13 in CD group and n = 10 in HFHCD group, pool of two independent experiments) (left), and t-SNE plots representing an overlay of total CD45⁺ cells (gray) and M-MDSC (red), PNM-MDSC (blue) and TAM (purple) (right). h gMFI of MHC II and (%) CD206⁺MHC II^lo in macrophages (M2 markers) in tumor and spleen (n = 9 in CD group and n = 7 in HFHCD group, unpaired t-test). i Expression of CD44 (%) and granzyme B (%) among CD8⁺ and NK cells in the tumor and spleen (n = 9 in CD group and n = 7 in HFHCD group). j B16-F10 proliferation was measured by 3H-Thymidine incorporation. B16-F10 were cultured, for 24 h, alone (n = 3) or with CD45⁺ cells isolated from CD (n = 5) or HFHCD tumors (n = 3). k Ki-67 immunohistochemistry staining was performed on FFPE tumor. (left) Quantification of % DAB staining and (right) representative picture of Ki-67 staining in the CD group (n = 9) and in the HFHCD group (n = 8). Scale bar = 100 µm. Data are expressed as mean ± s.e.m. Analysis of difference within groups were performed with Mann–Whitney t-test, and with one-way ANOVA with Bonferroni’s multiple adjustment test. Source data are provided as a Source Data file.